8VX0 image
Entry Detail
PDB ID:
8VX0
Keywords:
Title:
CRYSTAL STRUCTURE OF CYP2C9*14 IN COMPLEX WITH LOSARTAN
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2024-02-02
Release Date:
2024-06-12
Method Details:
Experimental Method:
Resolution:
3.05 Å
R-Value Free:
0.20
R-Value Work:
0.13
R-Value Observed:
0.14
Space Group:
I 2 2 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Cytochrome P450 2C9
Mutations:R125H
Chain IDs:A
Chain Length:473
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Structural and biophysical analysis of cytochrome P450 2C9*14 and *27 variants in complex with losartan.
J.Inorg.Biochem. 258 112622 112622 (2024)
PMID: 38852293 DOI: 10.1016/j.jinorgbio.2024.112622

Abstact

The human cytochrome P450 (CYP) 1, 2 and 3 families of enzymes are responsible for the biotransformation of a majority of the currently available pharmaceutical drugs. The highly polymorphic CYP2C9 predominantly metabolizes many drugs including anticoagulant S-warfarin, anti-hypertensive losartan, anti-diabetic tolbutamide, analgesic ibuprofen, etc. There are >80 single nucleotide changes identified in CYP2C9, many of which significantly alter the clearance of important drugs. Here we report the structural and biophysical analysis of two polymorphic variants, CYP2C9*14 (Arg125His) and CYP2C9*27 (Arg150Leu) complexed with losartan. The X-ray crystal structures of the CYP2C9*14 and *27 illustrate the binding of two losartan molecules, one in the active site near heme and another on the periphery. Both losartan molecules are bound in an identical conformation to that observed in the previously solved CYP2C9 wild-type complex, however, the number of losartan differs from the wild-type structure, which showed binding of three molecules. Additionally, isothermal titration calorimetry experiments reveal a lower binding affinity of losartan with *14 and *27 variants when compared to the wild-type. Overall, the results provide new insights into the effects of these genetic polymorphisms and suggests a possible mechanism contributing to reduced metabolic activity in patients carrying these alleles.

Legend

Protein

Chemical

Disease

Primary Citation of related structures